Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study

Arrowhead Pharmaceuticals presented interim Phase I/II data for ARO-MAPT, an investigational siRNA therapy designed to reduce tau protein expression in the central nervous system, along with initial clinical results for its TRiM CNS delivery platform. The article provides no efficacy, safety, or other numerical results.